Arkolith/Insider Trading/STSA/Form 4

Kollins John A

President and CEO, DirectorSatsuma Pharmaceuticals, Inc. (STSA) · full profile →Form 4 · filed Jun 8, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
1 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 6, 2023Tender(U)306K$0.91$278K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 8, 2023Disposed to issuer(D)128K——0
Jun 8, 2023Disposed to issuer(D)240K—$00
Jun 8, 2023Disposed to issuer(D)128K——0
Jun 8, 2023Disposed to issuer(D)128K—$00
Jun 8, 2023Disposed to issuer(D)277K—$00
Jun 8, 2023Disposed to issuer(D)505K—$00
Jun 8, 2023Disposed to issuer(D)175K—$00

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-014879) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML